Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 14/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876330 | 0.78 | PDE4A (0.31) | P2RX7 | |
| SCHEMBL30543166 | 0.78 | PDE10A (0.44) | JAK1 | |
| SCHEMBL25325041 | 0.78 | PDE10A (0.44) | JAK1 | |
| SCHEMBL25875863 | 0.76 | PDE2A (0.41) | — | |
| SCHEMBL25876131 | 0.75 | PDE9A (0.34) | — | |
| SCHEMBL25876233 | 0.74 | MAT2A (0.33) | — | |
| SCHEMBL25875942 | 0.74 | MAT2A (0.42) | — | |
| SCHEMBL25876352 | 0.74 | ADORA2A (0.34) | — | |
| SCHEMBL18789233 | 0.73 | CBLB (0.36) | JAK2 | |
| SCHEMBL25876077 | 0.72 | MERTK (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | P2RX7 2664/4885ATR 1954/4885ATRIP 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.